182 related articles for article (PubMed ID: 2930108)
1. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.
Pleskow DK; Berger HJ; Gyves J; Allen E; McLean A; Podolsky DK
Ann Intern Med; 1989 May; 110(9):704-9. PubMed ID: 2930108
[TBL] [Abstract][Full Text] [Related]
2. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease.
Ritts RE; Nagorney DM; Jacobsen DJ; Talbot RW; Zurawski VR
Pancreas; 1994 Nov; 9(6):707-16. PubMed ID: 7846013
[TBL] [Abstract][Full Text] [Related]
3. Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer.
Ching CK; Rhodes JM
Br J Cancer; 1989 Jun; 59(6):949-53. PubMed ID: 2736232
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas.
Steinberg WM; Gelfand R; Anderson KK; Glenn J; Kurtzman SH; Sindelar WF; Toskes PP
Gastroenterology; 1986 Feb; 90(2):343-9. PubMed ID: 2416628
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of non-invasive diagnostic tests in detecting cancer of the pancreas.
Wang JY; Chen FZ; Yang YZ
Chin Med J (Engl); 1990 Oct; 103(10):817-20. PubMed ID: 2125254
[TBL] [Abstract][Full Text] [Related]
6. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
[TBL] [Abstract][Full Text] [Related]
7. The clinical utility of the Ca19-9 radioimmunoassay for the diagnosis of pancreatic cancer presenting as pain or weight loss. A cost-effectiveness analysis.
Richter JM; Christensen MR; Rustgi AK; Silverstein MD
Arch Intern Med; 1989 Oct; 149(10):2292-7. PubMed ID: 2508587
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer.
Kiriyama S; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Ono H; Sakai Y
Cancer; 1990 Apr; 65(7):1557-61. PubMed ID: 2311067
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
[TBL] [Abstract][Full Text] [Related]
10. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA19-9 antigen.
Takeda S; Nakao A; Ichihara T; Suzuki Y; Nonami T; Harada A; Koshikawa T; Takagi H
Hepatogastroenterology; 1991 Apr; 38(2):143-8. PubMed ID: 1855772
[TBL] [Abstract][Full Text] [Related]
11. CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer.
Banfi G; Bravi S; Ardemagni A; Zerbi A
Int J Biol Markers; 1996; 11(2):77-81. PubMed ID: 8776607
[TBL] [Abstract][Full Text] [Related]
12. [Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) values in patients with pancreatic cancer or pancreatitis].
Changchine CS; Yung CY; Tzen KY
Changgeng Yi Xue Za Zhi; 1991 Mar; 14(1):32-8. PubMed ID: 2039968
[TBL] [Abstract][Full Text] [Related]
13. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma.
Safi F; Roscher R; Beger HG
Bull Cancer; 1990; 77(1):83-91. PubMed ID: 2180502
[TBL] [Abstract][Full Text] [Related]
14. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
15. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
16. Significance of adenocarcinoma-associated antigen YH206 levels in the pancreatic juice.
Imai K; Ban T; Endo T; Hinoda Y; Sugiyama T; Hirane T; Yabana T; Hirata K; Wada T; Yachi A
Gastroenterol Jpn; 1990 Feb; 25(1):112-6. PubMed ID: 2407594
[TBL] [Abstract][Full Text] [Related]
17. Levels of carcinoembryonic antigen and carbohydrate antigen (CA19-9) in pure pancreatic juice and sera in a patient with occult pancreatic cancer.
Okai T; Sawabu N; Takemori Y; Ohta H; Motoo Y; Kidani H
J Clin Gastroenterol; 1992 Sep; 15(2):162-4. PubMed ID: 1401832
[No Abstract] [Full Text] [Related]
18. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
19. Utility of tumor markers in determining resectability of pancreatic cancer.
Schlieman MG; Ho HS; Bold RJ
Arch Surg; 2003 Sep; 138(9):951-5; discussion 955-6. PubMed ID: 12963650
[TBL] [Abstract][Full Text] [Related]
20. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]